Vitamin K2 Ameliorates Diabetes-Associated Cognitive Decline by Reducing Oxidative Stress and Neuroinflammation

• Published in: Journal of neuroimmune pharmacology Vol. 19; no. 1; p. 56
• Main Authors: Chatterjee, Kaberi, Pal, Anubroto, Padhy, Dibya Sundar, Saha, Rajdeep, Chatterjee, Amrita, Bharadwaj, Monika, Sarkar, Biswatrish, Mazumder, Papiya Mitra, Banerjee, Sugato
• Format: Journal Article
• Language: English
• Published: New York Springer US 28.10.2024; Springer Nature B.V
• Subjects: Acetylcholinesterase - metabolism; Animals; Biomedical and Life Sciences; Biomedicine; Cell Biology; Cognitive Dysfunction - drug therapy; Cognitive Dysfunction - etiology; Cognitive Dysfunction - metabolism; Cognitive Dysfunction - prevention & control; Correspondence; Diabetes; Diabetes Mellitus, Experimental - complications; Diabetes Mellitus, Experimental - drug therapy; Diabetes Mellitus, Experimental - metabolism; GPI-Linked Proteins; Hippocampus - drug effects; Hippocampus - metabolism; Hippocampus - pathology; Immunology; Male; Maze Learning - drug effects; Mice; Neuroinflammatory Diseases - drug therapy; Neuroinflammatory Diseases - metabolism; Neurosciences; NF-E2-Related Factor 2 - metabolism; Oxidative stress; Oxidative Stress - drug effects; Pharmacology/Toxicology; Sirtuin 1 - metabolism; Virology; Inflammation; Antioxidant; Memory; Vitamin
• ISSN: 1557-1904; 1557-1890; 1557-1904
• DOI: 10.1007/s11481-024-10156-4

Diabetes, a chronic metabolic disease, affects approximately 422 million people and leads to 1.5 million deaths every year, It is found that 45% of individuals with diabetes eventually develop cognitive impairment. Here we study effects of Vitamin K2 on diabetes-associated cognitive decline (DACD) and its underlying mechanism. Diabetes was induced in adult Swiss albino mice with high-fat diet and a low dose (35 mg/kg) of streptozotocin and measured by fasting glucose and HbA1c levels. After one week of development of diabetes, one group of animals received Vitamin K2 (100 µg/kg) via oral gavage for 21 days. Then different behavioural studies, including the elevated plus maze, Morris water maze, passive avoidance test and novel object recognition test were performed followed by biochemical tests including AchE, different oxidative stress parameters (SOD, GSH, MDA, catalase, SIRT1, NRF2), inflammatory markers (TNFα, IL1β, MCP1, NFκB), apoptosis marker (Caspase 3). Hippocampal neuronal density was measured using histopathology. Vitamin K2 treatment in diabetic animals led to reduced fasting glucose and HbA1c, It could partially reverse DACD as shown by behavioural studies. Vitamin K2 adminstration reduced corticohippocampal AchE level and neuroinflammation (TNFα, IL1β, MCP1, NFκB, SIRT1). It reduced oxidative stress by increasing antioxidant enzymes (SOD, GSH, catalase), transcription factor NRF2 while reducing caspase 3. This eventually increased CA1 and CA3 neuronal density in diabetic animals. Vitamin K2 partially reverses DACD by increasing ACh while reducing the oxidative stress via Nrf2/ARE pathway and neuroinflammation, thus protecting the hippocampal neurons from diabetes associated damage.